Denopterin

Denopterin

SCHEMBL9294

CC(c1cnc2nc(N)nc(O)c2n1)N(C)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 11/20 0.62
KDM4E B2RXH2 1/20 0.62
TLR4 O00206 1/20 0.62
MEN1 O00255 1/20 0.62
ALDH1A1 P00352 1/20 0.62
LMNA P02545 1/20 0.62
TP53 P04637 1/20 0.62
TYMS P04818 1/20 0.62
GLA P06280 1/20 0.62
POLB P06746 1/20 0.62
HMGB1 P09429 1/20 0.62
MAPT P10636 1/20 0.62
FOLR2 P14207 1/20 0.62
FOLR1 P15328 1/20 0.62
HPGD P15428 1/20 0.62
ALOX15 P16050 1/20 0.62
ALOX12 P18054 1/20 0.62
GART P22102 1/20 0.62
APEX1 P27695 1/20 0.62
CASP1 P29466 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11494937 0.94 DHFR (0.55) DHFRKDM4ETLR4MEN1ALDH1A1
Adenopterin SCHEMBL19209756 0.92 DHFR (0.73) DHFRKDM4ETLR4MEN1ALDH1A1
Adenopterin SCHEMBL29499685 0.92 DHFR (0.73) DHFRKDM4ETLR4MEN1ALDH1A1
Adenopterin SCHEMBL19209757 0.92 DHFR (0.73) DHFRKDM4ETLR4MEN1ALDH1A1
Denopterin SCHEMBL5886040 0.91 FPGS (0.80) DHFRKDM4ETLR4MEN1ALDH1A1
SCHEMBL31561438 0.85 DHFR (0.64) DHFRKDM4ETLR4MEN1ALDH1A1
Denopterin SCHEMBL27499891 0.85 ADORA3 (0.67) DHFRKDM4ETLR4MEN1ALDH1A1
Denopterin SCHEMBL8937881 0.85 DHFR (0.49) DHFRKDM4ETLR4MEN1ALDH1A1
Bremfol SCHEMBL1649681 0.85 DHFR (0.64) DHFRKDM4ETLR4MEN1ALDH1A1
Bremfol SCHEMBL20228930 0.85 DHFR (0.64) DHFRKDM4ETLR4MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 22713 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4698185-A1 METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES Osasuna Therapeutics SA (CH) 2026-02-25 EP claimed
EP-4694909-A1 METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION RS Oncology, LLC (US) 2026-02-18 EP claimed
EP-4687999-A1 TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS OBI Pharma, Inc. (TW) 2026-02-11 EP claimed
EP-4676544-A1 ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF LigaChem Biosciences Inc. (KR) 2026-01-14 EP claimed
EP-3277381-B1 NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS OBI PHARMA INC (TW) 2026-01-07 EP claimed
WO-2000061549-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
WO-2000054795-A1 COMBINED THERAPY WITH A CHEMOTHERAPEUTIC AGENT AND AN ONCOLYTIC VIRUS FOR KILLING TUMOR CELLS IN A SUBJECT THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2000-09-21 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-1999058126-B1 USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES ENDOWMENT RES INHUMAN BIOLOGY (US) 2000-02-17 WO claimed
WO-1999058126-A1 USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 1999-11-18 WO claimed
WO-1998037898-A1 SYNERGISTICALLY ACTING ANTI-FUNGAL AGENTS THAT ARE INHIBITORS OF FOLATE METABOLISM, ESPECIALLY METHOTREXATE AND SULFAMETHOXAZOLE BARCLAY BARRY J (CA) 1998-09-03 WO claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed
EP-0641193-A4 CHEMOTHERAPEUTIC DRUG COMBINATIONS. MARTIN DANIEL S (US) 1995-09-06 EP claimed
EP-0641193-A1 CHEMOTHERAPEUTIC DRUG COMBINATIONS PRO-NEURON, INC. (US) 1995-03-08 EP claimed
WO-1993023014-A1 CHEMOTHERAPEUTIC DRUG COMBINATIONS MARTIN DANIEL S (US) 1993-11-25 WO claimed